首页> 外文期刊>Cancer radiotherapie: journal de la Soci閠?fran鏰ise de radiotherapie oncologique >Alpha/beta ratio revisited in the era of hypofractionation [Le rapport alpha/bêta revisité à l'heure de l'hypofractionnement]
【24h】

Alpha/beta ratio revisited in the era of hypofractionation [Le rapport alpha/bêta revisité à l'heure de l'hypofractionnement]

机译:在超分割时代重新审视α/β比值

获取原文
获取原文并翻译 | 示例
           

摘要

Large doses per fraction are not recommended in daily radiotherapy due to a higher risk of late normal tissue injury. The technical refinements of modern radiotherapy and suggestions that some tumors could be sensitive to dose per fraction have renewed the interest in hypofractionated schedules. The estimation of α/β ratio value requires large samples of carefully evaluated patients in whom total and fractional doses have varied independently. Tumor repopulation has to be considered when the treatment duration is altered. Without setting aside conflicting publication, the α/β ratio values for prostate and breast (after lumpectomy) cancers could be as low as 2.5. Gy and 4. Gy, respectively. While it is too early to change our routine protocols, the time has come to conduct clinical trials comparing different fractionation schedules.
机译:由于晚期正常组织损伤的风险较高,因此不建议每天放疗中每剂量使用大剂量。现代放射疗法的技术改进以及一些肿瘤可能对每部分剂量敏感的建议,已经使人们对低等时间表的兴趣再次兴起。 α/β比值的估计需要经过仔细评估的患者的大量样本,这些患者的总剂量和分数剂量均独立变化。当治疗时间改变时,必须考虑肿瘤的重新聚集。在不排除矛盾的出版物的情况下,前列腺癌和乳腺癌(肿块切除术后)的α/β比值可能低至2.5。 Gy和4. Gy。尽管现在更改常规方案还为时过早,但现在是进行比较不同分级方案的临床试验的时候了。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号